AOD9604, a fragment of Human Growth Hormone (HGH) comprising amino acids 177-191, has emerged as a potentially revolutionary therapeutic agent in the battle against obesity and its metabolic comorbidities. While the compound remains the subject of intensive research, preliminary studies point to a range of significant benefits, including:
Reduction of Body Fat: Research suggests that AOD9604 has the ability to stimulate lipolysis, the process by which fat cells release fatty acids, resulting in the breakdown and subsequent reduction of body fat.
Improvement of Lipid Metabolism: AOD9604 has been shown to positively influence lipid metabolism, potentially reducing total cholesterol and triglyceride levels while increasing high-density lipoprotein (HDL) cholesterol, known as "good" cholesterol.
Potential Benefit in Insulin Resistance: There is evidence suggesting that AOD9604 may improve insulin sensitivity, a crucial factor in regulating blood sugar levels and preventing type 2 diabetes.
Preservation of Muscle Mass: While promoting fat loss, studies indicate that AOD9604 may help preserve lean muscle mass, offering an additional benefit in maintaining metabolic function and physical strength.
Potential for Inflammation Reduction: Some preliminary studies suggest that AOD9604 may exert anti-inflammatory effects, which could have significant implications in reducing the risk of cardiovascular diseases and other conditions associated with chronic inflammation.
Despite these promising benefits, it is crucial to recognize that AOD9604 is still in the research and development stages. Further clinical studies are needed to assess its efficacy, safety, and potential adverse effects in a variety of populations. Additionally, the regulatory process for approving AOD9604 as a treatment for obesity may be lengthy and rigorous.
However, the therapeutic potential of AOD9604 offers an exciting prospect for addressing complex metabolic conditions such as obesity and may represent a new frontier in the field of personalized medicine and metabolic therapy. As research continues to advance, it is possible that AOD9604 could eventually play a significant role in improving health and quality of life for those affected by obesity and its metabolic complications.
AOD9604 5mg
The Development of AOD9604 from Human Growth Hormone
Investigators at Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 177-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone.
The Fat Loss Properties of AOD 9604
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the HGH fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, enhanced the burning of fat. In rodents (rats and mice), HGH fragment reduced body fat in obese animals but, enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted Growth Hormone effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.
These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Also, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Molecular formula: C78H123N23O23S2
Molar Mass: 1815.08152
CAS number: 221231-10-3
PubChem: CID 71300630
Synonyms:hGH Fragment 177-191, AOD-9604, 221231-10-